2024 European Breast Cancer Conference

By Caroline Helwick / September 25, 2024 / 2024 European Breast Cancer Conference

Phase III ALEXANDRA/IMpassion030: No Survival Benefit for Adjuvant Atezolizumab in Triple-Negative Breast Cancer

In patients with early-stage triple-negative breast cancer, the addition of atezolizumab to standard adjuvant chemotherapy provided no benefit over chemotherapy alone in the final analysis of the phas...

Breast Cancer

Genomics/Genetics

By Caroline Helwick / July 25, 2024 / 2024 European Breast Cancer Conference

New Genetic Test May Predict Response to Immunotherapy in Triple-Negative Breast Cancer

The search for biomarkers of response to immunotherapy is high on the list of cancer-related research efforts. A new classifier in triple-negative breast cancer is showing promise and is currently bei...

2024 European Breast Cancer Conference

Phase III ALEXANDRA/IMpassion030: No Survival Benefit for Adjuvant Atezolizumab in Triple-Negative Breast Cancer

New Genetic Test May Predict Response to Immunotherapy in Triple-Negative Breast Cancer

Outcomes of Immune Checkpoint Inhibitor Treatment for Cancer in Black vs White Patients in the U.S. VHA System

Pooled Analysis of Long-Term Outcomes With Nivolumab With or Without Ipilimumab in Advanced Melanoma

Neuro-Oncology Guidelines Reveal How AI Could Improve Brain Cancer Diagnosis Monitoring and Treatment

Firefighters May Be Exposed to Chemicals Associated With Breast Cancer

What Is the Impact of a Colon or Colorectal Cancer Diagnosis on Younger Adults?